by stemedica admin | Sep 30, 2019 | Clinical Trials
Study Sponsored by Stemedica Cell Technologies, Inc. SAN DIEGO, Calif. – (September 30, 2019) – Results from a study sponsored by Stemedica Cell Technologies, Inc., a global biotechnology company that uses allogeneic stem cells for ischemic conditions, form the basis...
by stemedica admin | Sep 13, 2019 | Clinical Trials, Publications
Abstract Background and Purpose Stroke is a leading cause of long-term disability. Limited treatment options exist for patients with chronic stroke and substantial functional deficits. The current study examined safety and preliminary efficacy estimates of intravenous...
by stemedica admin | Jan 7, 2019 | Clinical Trials
Stemedica Cell Technologies Reports Positive Data in Phase I/IIa Study of Allogeneic Stem Cells for Ischemic Stroke – itMSCs were safe and well tolerated in the study – – Results of the study are supportive of advancing clinical program – ...
by stemedica admin | Apr 18, 2018 | Clinical Trials, Publications, Subsidiaries
Washington, D.C., April 18, 2018 – Clinical trial planning is underway at MedStar Heart & Vascular Institute to determine whether a novel stem cell therapy will improve heart function for patients with heart failure. MedStar Heart, in partnership with CardioCell,...
by stemedica admin | Jul 27, 2016 | Clinical Trials
Initial Sites Are Emory University and University of California, Irvine SAN DIEGO, California, and Lausanne, Switzerland — July 27, 2016 — Stemedica Cell Technologies, Inc. and its subsidiary, Stemedica International S.A., a leader in the development of innovative...
by stemedica admin | May 18, 2016 | Clinical Trials
Clinical trial to study the effects of Stemedica’s proprietary mesenchymal stem cells in patients with traumatic brain injury SAN DIEGO, California – May 18, 2016. Stemedica Cell Technologies, Inc. (Stemedica) received an FDA investigational new drug (IND)...
